絞り込み

16555

広告

駿府城跡から豊臣秀吉が築かせた石垣跡 一般公開 (NHK)

徳川家康が築いた静岡市にある駿府城の天守台跡付近から、当時、ライバル関係にあった豊臣秀吉が築かせた石垣跡が見つかり、20日、一般公開されました。 静岡市によりま...

  1. ケニアの政府プロジェクトにブロックチェー...
  2. 再生医療、規制強化へ がん免疫療法の臨床...
  3. 4メートル超の大わらじ 浅草寺奉納へ出発...
  4. J-Startupをはじめとするベンチャ...

ニュース一覧

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.

著者 Reis R , Labat L , Allard M , Boudou-Rouquette P , Chapron J , Bellesoeur A , Thomas-Schoemann A , Arrondeau J , Giraud F , Alexandre J , Vidal M , Goldwasser F , Blanchet B
J Pharm Biomed Anal.2018 Jun 01 ; 158():174-183.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (36view , 0users)

Full Text Sources

Miscellaneous

A new method for the quantitative analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS) of five tyrosine kinase inhibitors (afatinib, crizotinib, osimertinib, erlotinib and nintedanib) used in the treatment of non-small cell lung cancer (NSCLC) was developed and validated in human plasma. Separation was performed on an Accucore C18 (2.1 × 50 mm; 2.6 μm) column using a gradient elution of water acidified with 0.1% (v/v) formic acid (A) and acetonitrile containing 0.1% (v/v) formic acid (B) at a flow rate of 500 μL/min. The analytes were detected in the selected reaction monitoring mode of a triple quadrupole mass spectrometer after positive ionization with heated electrospray interface. After addition of three isotopically labeled internal standards, plasma pretreatment consisted in a simple protein precipitation. This method presented satisfactory results in terms of sensitivity, specificity, precision (intra- and inter-assay coefficient of variation from 2.6% to 10.6%), accuracy (from 96.1% to 108.5%), recovery and matrix effects. The lower limit of quantification and the linearity of these five tyrosine kinases inhibitors are suitable with the expected concentrations in clinical practice. This new bioanalytical method can be used in daily clinical practice for therapeutic drug monitoring of these tyrosine kinase inhibitors in NSCLC patients.
PMID: 29883880 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード